- Home
- ELAB vs IMRN Comparison
ELAB vs IMRN Comparison
Compare ELAB & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELAB | IMRN |
|---|---|---|
| Founded | 2020 | 1994 |
| Country | United States | Australia |
| Employees | 34 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 8.2M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | ELAB | IMRN |
|---|---|---|
| Price | $1.65 | $1.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 546.8K | 144.0K |
| Earning Date | 05-14-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.68 |
| 52 Week High | $15.00 | $2.38 |
Technical Indicators
Market Signals| Indicator | ELAB | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 39.77 | 69.51 |
| Support Level | $1.65 | $0.72 |
| Resistance Level | $2.28 | $1.86 |
| Average True Range (ATR) | 0.19 | 0.18 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 2.29 | 65.82 |
Price Performance
Historical ComparisonAbout ELAB Elevai Labs Inc.
PMGC Holdings Inc IS advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.